Analgosedation in neonates: what we know and how we act

Karel Allegaert¹,²
Carlo V Bellieni³
¹Department of Development and Regeneration, KU Leuven and Neonatal Intensive Care Unit, University Hospitals Leuven, Belgium; ²Department of Pediatrics, Obstetrics and Reproduction Medicine, University of Siena, Siena, Italy

Abstract: Inadequate pain management in neonatal life impairs the neurodevelopmental outcome. It alters pain thresholds, pain and stress-related behavior, and physiologic responses in later life. At the same time, there are emerging animal experimental and human epidemiologic data on the impact of analgosedatives on neuroapoptosis and impaired neurodevelopmental outcome. As a consequence, the management of neonatal pain is in search of a new equilibrium since these conflicting (undertreatment versus overtreatment) observations are the main drivers of its current management. Such tailoring includes new treatment modalities, and also more effective implementation strategies. The search for tailored nonpharmacologic (ie, less invasive techniques, preventive strategies, complementary techniques) and pharmacologic (eg, dexmedetomidine, intravenous acetaminophen, remifentanil) treatment modalities are discussed and reflect the increased knowledge on neonatal pain management. Despite this increasing knowledge (‘toolbox’) regarding neonatal pain, there is still a major gap between knowledge (‘what we know’) and practice (‘how we act’). Consequently, more research activity on methods for effective implementation of the available knowledge is needed. Illustrations of effective approaches, eg, the Evidence-Based Practice for Improving Quality (EPIQ) initiative, to bridge this gap are provided. This is followed by an intersubjective proposal on priorities for contemporary clinical management and a research agenda.

Keywords: pain, newborn, prevention, guidelines

Introduction
Why pain management in neonates is of relevance

Already more than three decades ago, the myth that immaturity precludes neonates from pain perception and its negative effects was rejected by Anand et al when they documented that inadequate perioperative analgesia resulted in higher morbidity and mortality.¹ Moreover, it became apparent that these negative effects were not limited to neonatal life, but were also observed in later pediatric life and beyond.¹⁻⁴ In essence, adequate analgesia in neonates should not only been driven by empathy or ethics, but is valid, appropriate, and needed medical and nursing care.⁵

More recently, experimental data in animals have provided evidence that perinatal exposure to analgosedatives also results in reduced brain growth, decreased neuronal packing density, and less dendritic growth and branching.⁶⁻⁷ This is because of the impact of analgosedatives on axonal growth and apoptosis of neuronal tissue. There seems to be an age-related window of vulnerability for apoptosis or dendritic changes related to human neonatal life and infancy, respectively. These anatomic findings are associated with learning and motor disabilities.
Extrapolation of animal experimental observations to the human newborn are obviously limited and mainly based on associations. There are data on an association between major neonatal surgery (number of interventions, disease severity) and neurodevelopmental impairment. However, exposure to analgosedatives is only one of the factors associated with a negative outcome. Obviously, neonates who repeatedly undergo anesthesia during infancy are more likely to have other risk factors for impaired neurodevelopment. At the same time, we know from animal experiments and the clinical studies by Anand et al that surgery without analgesia has a major impact on morbidity and mortality.

Why pain management in neonates is different

From the above-mentioned arguments, it is obvious that effective pain management is an important indicator of the quality of care provided to neonates, not only from an ethical standpoint, but also in terms of protecting the long-term outcome. Neonates cannot assert their rights, and their reactions to pain are not so evident as in adults. Moreover, medical treatment initially has a strong focus on saving their lives, accepting that well-being is only secondary.

Now we know that babies are full patients in terms of their rights, and that neonates do feel pain and are even more vulnerable to pain. These more vulnerable neonates are precisely those that are most exposed to painful interventions. Finally, the subjectivity inherent in neonatal pain assessment probably further contributes to the wide variety of practices. All these reasons explain why pain management in neonates warrants a focused, population-tailored, individualized approach related to assessment, treatment, and preventive strategies since all these aspects (assessment, treatment, prevention) have population-specific issues (Figure 1).

Measurement/assessment

The absence of verbalization is very likely one of the most important obstacles to proper diagnosis, quantification, and treatment of neonatal pain. Pain in the newborn is often not easily recognized and remains commonly undertreated or untreated. In general, if a procedure is painful in adults, it should be considered painful in neonates. Because the pain threshold is lower in the newborn, it is reasonable that pain will be greater in neonates compared with adults for a similar procedure. Newborns depend completely on caregivers (parents, health care professionals) to recognize their needs. This includes aspects related to comfort and stress reduction.

---

**Figure 1** Why pain management in neonates warrants a focused approach.

---

Treatment

Maturational aspects affect drug dose (pharmacokinetics)
Changes in practices affect primary outcome variables (pharmacodynamics)

Assessment

Pain scales
Inter-subjectivity
Hetero-assessment

Prevention

Growing evidence on effectiveness of non-pharmacological modalities

Individualized approach

Combination of unit specific guidelines and the individual needs of the newborn
and should cover evaluation/assessment, prevention, and management of pain.\textsuperscript{4,9}

**Treatment**

When we apply the concept of developmental pharmacology to analgosedatives in neonates, this should be based on systematic assessment (pharmacodynamics, concentration-effect), titrated administration of the most appropriate analgesia (pharmacokinetics, concentration-time), and reassessment (pharmacodynamics) to adapt and titrate exposure to effects (pharmacodynamics).\textsuperscript{5}

Clinical management and subsequent primary pharmacodynamic outcome variables shifted. To illustrate this, respiratory support after surfactant administration (InSuRe [Intubation, Surfactant and Rapid Extubation]) is much more common than prolonged ventilation, and hypothermia has been introduced as an effective tool to treat peripartum asphyxia.\textsuperscript{9} This results in the need for new pharmacokinetic/pharmacodynamic data in new (sub)populations.

**Preventive strategies**

Environmental (noise, light), behavioral (positioning) and nonpharmacologic (sucrose, breastfeeding, pacifier) interventions can prevent, reduce, or eliminate pain and may improve comfort. Such interventions need to be validated first, and subsequently compared and integrated in routine care.\textsuperscript{14–17} Following validation, emphasis should be placed on integration. Promotion of clinical research, diffusion of knowledge, and validation of the effectiveness of implementation strategies to improve analgosedation remain crucial.\textsuperscript{14–17}

**Despite this, we do not stick to the guidelines**

Despite ethical issues, increasing awareness, and the availability of guidelines on procedural pain, neonates still often experience avoidable pain.\textsuperscript{18} The discrepancy between the available knowledge and clinical practice has been reillustrated by Carbajal et al.\textsuperscript{19} Epidemiologic data on the incidence of painful procedures and their management during the first 14 days of admission were prospectively collected over a 6-week period (2005–2006) in 430 neonates admitted to tertiary care neonatal intensive care units in the Paris region of France. Of 42,413 painful procedures identified, 2.1\% were performed with pharmacologic therapy only, 18.2\% with nonpharmacologic therapy only, 20.8\% with pharmacologic and nonpharmacologic therapy, and 79.2\% without specific analgesia; 34.2\% were performed while the neonate was receiving concurrent analgesic or anesthetic infusions for other reasons. Consequently, the investigators concluded that large numbers of procedures were performed and most were not accompanied by analgesia.\textsuperscript{19} These findings are unfortunately very similar to the data published by Simons et al and collected 5 years earlier.\textsuperscript{20} In their dataset comprising 151 preterm neonates, each neonate was subjected to 14±4 procedures per day. Pre-emptive analgesia was provided to less than 35\% of these neonates, and about 40\% did not receive any analgesic therapy during their stay in the neonatal intensive care unit.\textsuperscript{20}

Similar results were reported when practices were compared between two time intervals in the same region.\textsuperscript{21,22} Survey data on analgesia policy and practices for common invasive procedures at Italian neonatal intensive care units were compared for the years 2004 and 2010 to ascertain the extent to which neonatal analgesia for invasive procedures has changed since publication of the Italian guidelines. According to paired data from 75 neonatal intensive care units, the practice of pain monitoring has become more common. However, only 21\% and 17\% of neonatal intensive care units routinely assessed pain during mechanical ventilation and after surgery, respectively. Similarly, routine use of medication for major invasive procedures was still limited (35\% of lumbar punctures, 40\% of tracheal intubations, 46\% during mechanical ventilation) and postoperative pain treatment was also inadequate. Consequently, the authors concluded that despite the improvements in neonatal analgesia practices in Italy since the national guidelines were published, pain is still largely undertreated and underscored in this age group.\textsuperscript{21,22} Similar conclusions can be drawn when we focus on pain management during a specific procedure (heel lancing, Europe),\textsuperscript{23} or on pain assessment (Sweden).\textsuperscript{24} At the least, there is still room for improvement.

This review illustrates the progress made in the search for better tailored nonpharmacologic and pharmacologic interventions, without being a systematic review of all studies reported on such interventions in neonates. Tailored nonpharmacologic interventions focus on less invasive techniques, preventive strategies, and complementary techniques. Tailored pharmacologic interventions focus on new compounds (dexametomidine, intravenous acetaminophen, remifentanil). In addition to providing additional knowledge on neonatal pain management, we also focus on the need to do more research regarding methods for effective implementation of such knowledge. This is because there is still a gap between knowledge (what we know) and practice (how we act). Illustrations of effective approaches to bridge this
Tailored nonpharmacologic treatment: intensive “care” in addition to intensive “cure” Not only what but also how we perform procedures matters

Environmental (noise, light), behavioral (positioning), and nonpharmacologic (sucrose, breastfeeding, pacifier) interventions can prevent, reduce, or eliminate pain, and may improve comfort. Adaptations of procedural techniques or practices may be a very powerful method of preventing pain and reducing stress. Such strategies include light and noise reduction, nesting or swaddling, minimizing patient handling (eg, preserving free periods for sleep, avoiding consecutive blood sampling, clustered care), use of central venous catheters instead of multiple peripheral perfusions, individualized monitoring techniques (registration of vital signs, blood pressure measurement intervals), tailoring nursing techniques (eg, frequency of endotracheal suctioning, skin and wound care, tape and wound dressing), and promoting skin-to-skin contact between newborns and parents. In essence, methods matter, and adaptations of existing techniques can be very effective in reducing pain. The available evidence is illustrated based on published data related to venous blood sampling and endotracheal suctioning in neonates.

Venous blood sampling is commonly performed in neonates. In addition to complementary interventions like non-nutritive sucking, sucrose, or containment, the technique used for blood sampling is also of relevance, as shown in two studies including 120 and 100 healthy term neonates. In the study by Larsson et al, venepuncture by needle was compared with either a small or large lancet (heel lancet). Sampling with only one skin puncture was successful in 86% (needle puncture), 19% (small), and 40% (large lancet) of cases, and median time for collection was 191, 419, and 279 seconds, respectively. Lower pain (Neonatal Facial Coding) scores were recorded in the needle group than using either of the heel lancing techniques. Similar observations were reported in a study by Ogawa et al in which 100 healthy term neonates were randomly allocated one of four groups (venepuncture versus heel lancing, oral sucrose versus water). Using this design, the Neonatal Facial Coding score was significantly lower in the venepuncture group (230 versus 580).

Interestingly, the lancing with sucrose group still had higher scores compared with the venepuncture without sucrose group (470 versus 230).

Endotracheal suctioning is also a stressful procedure, commonly associated with pronounced fluctuations in vital signs. Cordero et al compared two endotracheal suctioning frequencies in preterm neonates and concluded that there was no benefit of systematic routine suctioning when compared with suctioning as needed. Based on these findings, an evidence-based protocol whereby ventilated newborns were suctioned only as needed according to clinical indicators was developed. This protocol was subsequently introduced as part of a collaborative quality improvement initiative and resulted in a significant decrease in the number of procedures performed.

In addition to frequency of suctioning, procedural adaptations (disconnection, deep versus shallow) may also reduce distress. There is evidence to suggest that endotracheal suctioning without disconnection improves the short-term outcome when focusing on vital signs, likely reflecting a reduced stress response. In contrast, there is no evidence of the benefits or risks of deep versus shallow suctioning of endotracheal tubes in ventilated neonates. Disconnection and deep versus shallow endotracheal suctioning have been evaluated in two recent Cochrane meta-analyses. Using a crossover design in 252 infants to compare endotracheal suctioning with or without disconnection, suctioning without disconnection resulted in a reduction in both frequency and severity of hypoxic events. Similarly, endotracheal suctioning without disconnection resulted in a more limited change in heart rate. The number of infants having bradycardic events was also reduced during closed suctioning. Interestingly, four-handed care to facilitate containment during endotracheal suctioning also resulted in a significant decrease in stress and defense behavior.

Add-on value of nonpharmacologic interventions

Awareness of the persistently high number of painful procedures performed, combined with concerns regarding the potential adverse effects of drugs and perhaps also the aim to involve parents, has resulted in evaluation of alternative, nonpharmacologic interventions in neonates. Nonpharmacologic interventions have wide applicability for neonatal pain management alone or in combination with pharmacologic treatments. These interventions are not necessarily substitutes for or alternatives to pharmacologic interventions, but are complementary. Nonpharmacologic interventions can reduce neonatal pain indirectly by reducing
the total amount of noxious stimuli and directly by blocking nociceptive transduction or transmission, activation of descending inhibitory pathways, or by activating attention and arousal systems that modulate pain. Non-nutritive sucking, providing sucrose, glucose, or human milk, swaddling and containment procedures, sensory stimulation, and kangaroo care are complementary interventions. Some of the available evidence on the benefit for analgesedation in neonates is summarized here.

Non-nutritive sucking
There is limited evidence on the use of non-nutritive sucking as a single intervention to promote behavioral outcomes and gastrointestinal function or feeding tolerance in preterm and high-risk full-term infants, but it has been linked to a reduced length of hospital stay and improved pain management. Non-nutritive sucking does not appear to have any short-term negative effects, but data on long-term outcome are not available. For procedural pain management, pacifiers reduce pain scores in neonates.

Sucrose, glucose, and human milk
The most extensively evaluated nonpharmacologic intervention for procedural pain relief in neonates is oral sucrose (12%–24%), glucose (30%), or mother’s milk, with or without non-nutritive sucking (pacifier). It is believed that the effects of sucrose and non-nutritive sucking are mediated by both the endogenous opioid and nonopioid systems. There is meta-analytical evidence in support of the use of oral sucrose 24%, glucose 30%, or mother’s milk in combination with a pacifier shortly before a painful procedure (eg, blood sampling, nasogastric tube placement, immunization/vaccination). Compared with topical anesthesia, acetaminophen, or morphine, glucose/sucrose resulted in the most prominent decrease in pain during heel prick procedures. Consequently, this became the most commonly used intervention for procedural analgesia in neonates. To make it more effective, this should be combined with use of a pacifier and the sweet solution should be administered on the tongue shortly (2 minutes) before the start of the intervention. This time interval is thought to reflect endogenous opioid release. Interestingly, breastfeeding in addition to holding and skin-to-skin contact provided superior analgesia during heel prick when compared with sucrose with or without skin-to-skin contact.

Swaddling and containment
Preterm infants show improved neuromuscular development, less physiologic distress, better motor organization, and more self-regulatory ability when swaddled. When compared with massage alone, excessively crying infants cried less when swaddled. In neonatal intensive care units, the data are somewhat more contradictory. In meta-analysis, it seems that swaddling has a pain-reducing effect, maintained for longer in term neonates than in preterm neonates. Because the primary outcomes of studies related to swaddling and containment are less commonly summarized, an illustrative overview of studies on facilitated tucking in of (pre)term neonates (either or not combined or compared with other complementary interventions) is provided in Table 1. Most of these studies were not blinded, had a crossover design, and order effects are rarely reported. However, the available evidence suggests a modest reduction in pain with a faster return of physiologic fluctuations to baseline. Facilitated tucking alone was less effective when compared with use of sucrose. However, facilitated tucking in combination with sucrose had an added value (ie, synergism) in the recovery phase, with lower pain scores compared with both single interventions. The same synergism concept has been documented when combining breastfeeding with skin-to-skin contact for analgesia during heel prick.

Multisensorial stimulation and sensorial saturation
Sensorial saturation refers to multisensorial stimulation consisting of simultaneous delicate tactile, gustative, auditory, and visual stimuli. This procedure consists of simultaneously attracting the infant’s attention by massaging the infant’s face; speaking to the infant gently but firmly, and instilling a sweet solution on the infant’s tongue. Nonpainful stimulation by engaging a number of channels (ie, auditory, tactile, visual, vestibular, gustatory) is thought to compete with the painful sensory input. In a recent systematic review on this topic, ten studies were retrieved that had evaluated at least partial sensorial saturation. Based on the evidence collected, the use of an oral solution alone seemed to be less effective than sensorial saturation, while sensorial stimulation without a sweet oral solution was ineffective. Consequently, it was concluded that sensorial saturation could be used for newborns undergoing minor painful procedures. It is more effective than oral sugar alone and promotes interaction between the caregiver and infant.

Tailored pharmacologic treatment modalities
When the concepts of neonatal pharmacology are applied to neonatal analgesedation, they should be based on systematic assessment, followed by correct (eg, titrated administration,
Table 1 Studies on facilitated tucking combined or compared with other complementary interventions

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study design</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corff et al</td>
<td>Randomized crossover study in 30 preterm neonates (25–35 weeks) to compare the effects of facilitated tucking with those of routine care on vital signs and sleep disruption. Facilitated tucking resulted in a lower heart rate, a shorter crying time, and less sleep disruption.</td>
</tr>
<tr>
<td>Fearon et al</td>
<td>Responses of 15 preterm neonates to swaddling after a heel lance were quantified. Protracted behavioral disturbances were reduced by swaddling.</td>
</tr>
<tr>
<td>Ward-Larson et al</td>
<td>Randomized crossover study in 40 preterm neonates (23–32 weeks) to assess the impact of facilitated tucking (second nurse) on pain related to endotracheal suctioning. Pain expression during facilitated tucking was significantly lower.</td>
</tr>
<tr>
<td>Hill et al</td>
<td>Randomized crossover study in 12 preterm neonates (25–34 weeks) to compare the impact of facilitated tucking with routine care on the stress response during routine nursing assessments. Nine of 12 infants received a lower PiPP score with facilitated tucking.</td>
</tr>
<tr>
<td>Axelin et al</td>
<td>Prospective, randomized controlled trial in 20 preterm neonates (24–33 weeks) to assess the impact of facilitated tucking by parents on pain expression (NiPS) and vital signs during endotracheal/pharyngeal suctioning. Facilitated tucking resulted in a lower NiPS (median 3–5) score.</td>
</tr>
<tr>
<td>Liaw et al</td>
<td>Randomized, controlled crossover trial in 34 preterm neonates (29–37 weeks) to compare non-nutritive sucking with facilitated tucking and routine care on pain response after heel lancing. Both facilitated tucking and non-nutritive sucking resulted in a reduced pain response, but non-nutritive sucking was more effective.</td>
</tr>
<tr>
<td>Cignacco et al</td>
<td>Randomized controlled trial in 71 neonates (24–32 weeks) to assess the effect of sucrose, facilitated tucking, or both, on the pain response following heel lancing. Facilitated tucking was less effective compared with sucrose. Combination of both interventions resulted in synergism.</td>
</tr>
<tr>
<td>Liaw et al</td>
<td>Randomized controlled trial to assess the impact of non-nutritive sucking, sucrose, and facilitated tucking either alone or combined on sleep-wake states after heel lancing in 110 infants (gestational age 26.4–37 weeks). Combined non-nutritive sucking, sucrose, and facilitated tucking resulted in the best preservation of the infant’s sleep-wake states.</td>
</tr>
<tr>
<td>Sundaram et al</td>
<td>Randomized, controlled, crossover pilot study in 20 preterm neonates (28–36 weeks) to compare the impact of facilitated tucking with no intervention after heel lancing. Facilitated tucking resulted in significantly lower pain scores.</td>
</tr>
<tr>
<td>Gerull et al</td>
<td>Compare the influence of facilitated tucking, sucrose, or both on cortical activation, heart rate, and peripheral oxygen saturation (SaO2) after 125 heel lancing procedures. Sucrose was more effective in reducing the reaction to pain than facilitated tucking. Application of both interventions had no additive effect.</td>
</tr>
<tr>
<td>Marin Gabriel et al</td>
<td>Breastfeeding with skin-to-skin contact, compared with sucrose with or without skin-to-skin contact during heel lancing.</td>
</tr>
</tbody>
</table>

Abbreviations: NiPS, Neonatal Infant Pain Scale; PiPP, Premature Infant Pain Profile.

loading dose) administration of the most appropriate analgesicative (eg, effects/side effects) with subsequent reassessment of the newborn and, if indicated, further adaptation (eg, increase, decrease, synergism).59 We aim to illustrate the progress made based on aspects of the pharmacokinetics and pharmacodynamics of specific newly emerging compounds (dexmedetomidine, intravenous paracetamol, remifentanil) in neonates. Although these compounds have “dipped” into our units, we need to be aware that the evidence in support of these newer compounds is still limited.

Dexmedetomidine

Optimal analgesedation is rapid in onset, predictable, unrelated to active metabolites, and shows rapid dissipation of effects on discontinuation. Preferably, the drug is nonaddictive (physical dependence or withdrawal on discontinuation), and without tolerance or adverse effects.50,51 Dexmedetomidine may become a potentially useful compound to attain this in neonates. Dexmedetomidine is a strongly lipophilic α2-adrenoreceptor agonist with a α2/α1 activity ratio of 1,620/1. Its mechanism of action is via G-protein activation central postsynaptic α2-adrenoreceptors, leading to inhibition of norepinephrine release, resulting in sedative, analgesic, opioid-sparing, and anxiolytic properties, as well as side effects such as hypotension or bradycardia.50,51

Dexmedetomidine has many claimed theoretical advantages over standard sedatives with regard to adverse drug reactions and does not affect respiratory drive.52–54 At present, clinical experience with dexmedetomidine in neonates is only anecdotal.51 However, it holds promise as a useful tool for analgesedation in neonates.50–54 Data are not yet available to formulate any recommendation, except for the fact that this drug should only be used in clinical studies to obtain valid data on the risk/benefit profile in neonates.

Acetaminophen

Acetaminophen is the most commonly prescribed drug for mild to moderate pain, including in neonates. In addition to enteral formulations, intravenous formulations are available. Such formulations enable administration when the enteral route cannot (yet) be used and should improve predictability by reducing variability in absorption.52 The effect
compartment concentration for acetaminophen of 10 mg/L is achieved following administration of a loading dose.\textsuperscript{56,57} Compared with opioids, tolerance does not develop during repeated administration, but there is an analgesic ceiling effect.\textsuperscript{56,57} Based on these facts, the concept of multimodal analgesia has been introduced in neonatal intensive care. Very recently, Ceele et al documented a clinically relevant and significant (–66%) morphine-sparing effect in neonates cotreated with intravenous acetaminophen following major noncardiac surgery, thereby documenting the validity of multimodal analgesia in neonates.\textsuperscript{58}

In contrast, acetaminophen has a limited analgesic effect for procedure-related pain. Shah et al documented that administration of acetaminophen (20 mg/kg orally) was ineffective for pain relief related to heel prick.\textsuperscript{59} The effects of acetaminophen (20 mg/kg rectally) in neonates following vacuum extraction has been documented by Van Lingen et al.\textsuperscript{60} Acetaminophen improved their clinical condition (eg, drinking behavior), but without differences in pain scores. Very recently, using a preemptive approach (ie, in all cases, irrespective of pain score) in 123 term neonates following assisted vaginal delivery, infants born by assisted vaginal delivery had low pain scores in the immediate period after birth, irrespective of acetaminophen exposure.\textsuperscript{61} However, acetaminophen (20–25 mg/kg rectally) given to term newborns shortly after birth was associated with an aggravated subsequent stress response during heel lancing on day 2–3 of postnatal life.\textsuperscript{61}

**Remifentanil**

Besides morphine and fentanyl, there are also observations on shorter-acting opioids in neonates. Alfentanil, sufentanil, and more recently remifentanil have been evaluated, mainly for short procedures such as endotracheal intubation, retinal laser surgery, or percutaneous intravenous central catheter placement, and there is some anecdotal experience during major surgery or maintaining analgosedation during mechanical ventilation.\textsuperscript{62} Remifentanil hydrochloride is a short-acting \(\mu\)-receptor opioid agonist. It achieves its peak analgesic effect within a minute of administration, ie, 3–4 times faster when compared with fentanyl and much faster in comparison with morphine.\textsuperscript{62}

Table 2 summarizes the studies on endotracheal intubation with remifentanil in neonates, and illustrates the variability in strategies and outcome criteria.\textsuperscript{63–67} There is variability in the clinical characteristics (preterm or term, use of InSuRE, or continuation of ventilation), outcome criteria (intubation score, duration of procedure, physiologic variables), comedication, and doses (1–4 \(\mu\)g/kg intravenously, slow bolus) evaluated. The total number of neonates exposed to remifentanil in these studies suggests that further studies on dose-seeking and safety are needed. To assess the analgesic and procedural efficacy of low-dose remifentanil infusion during percutaneous central catheter placement in preterm infants, 54 preterm neonates were assigned to remifentanil infusion (0.03 \(\mu\)g/kg per minute) or placebo in addition to 0.3 mL of 12% oral sucrose combined with non-nutritive sucking.\textsuperscript{68} Pain scores were significantly lower in neonates exposed to remifentanil, suggesting better pain and distress control without a difference in duration of the procedure. In essence, remifentanil is a very short-acting compound with limited reported experience in neonates at this time. Its pharmacologic profile seems suited for short

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study design and results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pereira e Silva et al\textsuperscript{63}</td>
<td>Double-blind, randomized controlled trial in 20 preterm neonates (28–34 weeks) to evaluate intubation conditions following morphine 150 (\mu)g/kg or remifentanil 1 (\mu)g/kg, both with midazolam 0.2 mg/kg. Overall condition was better in the remifentanil group.</td>
</tr>
<tr>
<td>Welzing et al\textsuperscript{64}</td>
<td>Prospective study in 21 preterm neonates (29–31 weeks) treated with remifentanil 2 (\mu)g/kg and atropine 10 (\mu)g/kg for the InSuRE procedure. Outcome variables were intubation conditions, time until extubation, and complications. Intubation conditions were rated as excellent or good. Average extubation time after surfactant was 16.9 (range 1–45) minutes.</td>
</tr>
<tr>
<td>Choong et al\textsuperscript{65}</td>
<td>Double-blind, randomized controlled trial in 30 (pre)term neonates. Remifentanil 3 (\mu)g/kg was compared with fentanyl 2 (\mu)g/kg and succinylcholine 2 mg/kg. No differences were found in time until successful intubation (156/247 seconds). Premedication with remifentanil attenuated physiologic responses during intubation comparable with those of fentanyl and succinylcholine in neonates. Intubation conditions were rated more favorably with fentanyl and succinylcholine. Muscular rigidity was observed in the remifentanil group (n=2/15).</td>
</tr>
<tr>
<td>Hume-Smith et al\textsuperscript{66}</td>
<td>Remifentanil effective dose-seeking (ED\textsubscript{50}) study in 20 neonates and young infants (mean weight 5.9 kg). When coadministered with glycopyrrolate 10 (\mu)g/kg and propofol 5 mg/kg, the ED\textsubscript{50} of remifentanil was 3.1–3.5 (\mu)g/kg.</td>
</tr>
<tr>
<td>Norman et al\textsuperscript{67}</td>
<td>Randomized controlled trial in 34 preterm neonates (&lt;37 weeks). Atropine/morphine compared with glycopyrrolate, thiopental, suxamethonium, and remifentanil (1 (\mu)g/kg). Intubation score was superior in the remifentanil group [5 (IQR 5–6) to 12 (IQR 10–13.5)]. Fluctuations in physiologic variables were more pronounced and prolonged after morphine.</td>
</tr>
</tbody>
</table>

**Abbreviations:** InSuRE, Intubation, Surfactant and Rapid Extubation; IQR, interquartile range.
procedure-related analgosedation. Its good predictability, rapid onset of action, and rapid disappearance are suggested to be advantageous. Clinicians also need to be aware of the potentially rapid development of tolerance, the phenomenon of hyperalgesia, and the potential risk of chest rigidity.

**Collaborative initiatives for quality improvement and effective implementation in daily practice**

A promising approach to facilitate implementation of better practices to improve pain management in neonates has been described by Dunbar et al. Twelve neonatal intensive care units in the Neonatal Intensive Care Quality Improvement Collaboration focused on improving neonatal pain and sedation practices. In essence, these units developed and subsequently implemented evidence-based practices for pain management and sedation in neonates using the EPIQ approach. This strategy emerges as an effective tool for quality improvement within and between neonatal intensive care units, and not limited only to pain management. In essence, this strategy is based on a stepwise approach. First, the group of units introduced changes through plan-do-study-act cycles and tracked performance measures throughout. Strategies for implementing potentially better practices varied between neonatal intensive care units on the basis of local characteristics. Individual units identified their barriers to implementation, developed tools for improvement, and subsequently shared their experience with the collaborative. Using this approach of collaborative quality improvement techniques enhanced local quality improvement efforts, and resulted in effective implementation of potentially better practices at participating neonatal intensive care units.

Similarly structured initiatives have been reported recently by Zhu et al in Canada and Dienld et al in Austria. Zhu et al reported that knowledge translation initiatives focusing on education, reminders, audit, and feedback had a positive effect on documentation of pain assessment, pain management, pain prevalence, and pain intensity. A similar approach, focusing on care providers and protocol-driven pain management, has been reported by two Austrian neonatal units. A potentially powerful tool for making progress may be to integrate parents into the health care team, as has been described earlier for facilitated tucking. Taddio et al recently reported on the development of a parent-directed educational pamphlet and video about the management of vaccination-related pain in infancy, and thereby illustrated a valid approach to developing parent-tailored tools.

**On contemporary pain management and a clinical research agenda**

Nonpharmacologic and pharmacologic pain management became an indicator of quality of care provided to neonates following the pivotal publications by Anand et al. In the meantime, neonatal care itself has also evolved towards less invasive care, as reflected by the introduction of minimal enteral feeding to shorten the duration of parenteral nutrition while the duration of endotracheal ventilation is shortened through early nasal continuous positive airway pressure or the InSuRe approach. The emerging data on pain management and shifts in clinical care resulted in the need for a new equipoise. This new equipoise has an impact on contemporary pain management and affects the clinical research agenda. Although to a large extent our subjective opinion, contemporary management relates to the three issues mentioned below, ie, pain management is not a stand-alone activity, needs a structured approach, and new techniques and drugs do potentially result in new (side) effects.

**Effective neonatal pain management is not a stand-alone activity**

Effective neonatal pain management should be an integrated part of developmental care. Further evidence of this comes from the finding that improved behavioral outcome in former preterm infants was associated with both the level of developmental care and pain management provided during their neonatal stay. A higher level of developmental care was associated with higher scores for attention and regulation, less excitability, and lower stress scores, while a higher level of neonatal pain management was associated with higher attention and arousal and less lethargy. The association between developmental care and pain management suggests that the combination of both support better neurobehavioral stability.

**Structured approach for pain management is needed**

There is no doubt that all neonatal intensive care units need to adapt a validated pain assessment tool and an algorithm outlining the responses of health care providers if abnormal pain scores are detected. This has recently been reillustrated. Reaching consensus within the neonatal intensive care unit care team on interpretation of an abnormal pain score and developing an algorithm of care for each pain scenario is crucially important. The same algorithm should also provide
New techniques result in new side effects

Potential new side effects include opioid tolerance, neonatal withdrawal syndrome, hyperalgesia, and drug-related toxicities. Caregivers should familiarize themselves with the contemporary management of these side effects, and any protocol should aim to limit the number of pharmacologic treatment modalities used within any given neonatal intensive care unit. It is better to build experience on the effect and side effect profile of a limited number of compounds, instead of going for a “drug of the month” approach.5,9,73

Improvement in current knowledge is obviously needed. This needs to be done based on different types of studies. However, we do suggest that such a clinical research agenda covers the following:

1. Development and validation of more sophisticated pain assessment tools integrating neurobiologic evaluation. At present, we measure at the level of pain expression, which is not equal to nociception or pain perception.11,76,77

2. Collection of long-term outcome data after neonatal exposure to analgosedatives is urgently needed, in line with the need for pharmacovigilance regarding other drugs commonly administered to neonates.

3. An appropriate study design is required for neonatal pain studies. It is obvious that pain should be avoided in the design of these studies, necessitating consideration of the “placebo” component of any trial.78,79 However, we also need to take potential overdosing into account. Consequently, we encourage clinicians, as well as the ethical committees and other stakeholders involved, to design dose-finding studies, which are needed to improve adequate (effective, neither overexposure nor underexposure) administration of analgosedatives in neonates.

The experimental observations in animals concerning neuroapoptosis force us to reconsider the modalities used, including both drugs and the doses administered. Although any study design can be criticized, the report by Ceelie et al on the effect of acetaminophen on post-operative morphine needs in neonates illustrates such a balanced approach in study design.58,80

Acknowledgment

KA is supported by the Fund for Scientific Research, Flanders (Fundamental Clinical Investigatorship 1800214N).

Disclosure

The authors report no conflicts of interest in this work.

References


